Academia
On this page, you will find information on the European Medicines Agency’s (EMA) activities that are most relevant to academia, including news and events. Learn more about the Agency's resources to support medicine development:
Human regulatory: Research and development
Veterinary regulatory: Research and development
Learn more about how EMA interacts with academia.
Featured information
-
List item
Coronavirus disease (COVID-19)
Keep up to date with the latest information on how EMA is handling the COVID-19 pandemic.
-
List item
Electronic product information
In January 2020, EMA, the Heads of Medicines Agencies and the European Commission published key principles to guide the development and use of electronic product information (ePI) for human medicines in the EU. This aims to improve access to up-to-date product information on medicines when and where it is needed.
-
List item
From lab to patient: journey of a medicine
EMA's new interactive timeline illustrates the journey of a medicine for human use assessed by EMA. It explains all stages from initial research to patient access, including how EMA supports medicine development, assesses the benefits and risks and monitors the safety of medicines. This initiative aims to improve understanding of how EMA works.
-
List item
European Reference Networks
European Reference Networks (ERNs) are virtual networks involving healthcare providers across Europe. They aim to facilitate discussion on complex or rare diseases and conditions that require highly specialised treatment and concentrated knowledge and resources. Information videos and flyers are available for patients and healthcare professionals on the European Commission’s website.
-
List item
Horizon 2020 research funding
EMA has published a dedicated webpage with information that may be helpful for researchers applying for funding under the European Commission's Horizon 2020 programme in the area of health.
-
List item
Supporting medicine developers
EMA's infosheet highlights the regulatory tools EMA offers to support the development of new and innovative medicines – from the early phases in the laboratory all the way to the patient.